Evaluation of the immunogenicity and safety of a booster dose of Pfizer's 13-valent pneumococcal conjugate vaccine in children primed with 3 doses of either GSK's 10-valent pneumococcal conjugate vaccine or Pfizer's 13-valent pneumococcal conjugate vaccine in the Czech Republic. [Vyhodnoceni imunogenity a bezpecnosti posilovaci davky 13valentni pneumokokove konjugovane vakciny firmy Pfizer u deti po zakladnim schematu ockovani 3 davkami 10valentni pneumokokove konjugovane vakciny firmy GSK nebo 13valentni pneumokokove konjugovane vakciny firmy Pfizer v Ceske republice]
Latest Information Update: 27 Aug 2023
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Pharmacodynamics; Registrational
- Acronyms PCV-MIXED-SCHEDULE
- 13 Dec 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 20 Feb 2013 New trial record